Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Medwell Capital Corp V.MWC

Sector: Financial Services | Sub-Sector: Asset Management
Alternate Symbol(s):  V.WMC

Medwell Capital Corp is an advisory firm which directly invests in and advises companies on strategy and technology development. It invests in healthcare sector.
Price: $1.55 | Change: $0.00 | %Change: 0.00%
Volume: 135 | Day High/Low: 1.55/1.55 | 52 Week High/Low: 2.01/0.98

Snapshot

Last Traded: August 19, 2014 10:11 Transaction Volume: 135
Open: $1.55 Previous Close: $1.55
Bid: $1.55 Ask: $1.65
Bid Size: 5,100 Ask Size: 300
Market Cap: $11.3m Shares Out: 7.3m
PE Ratio: N/A Dividend Yield: N/A
Scale: 1d 5d 3m 6m 1y 2y 5y
Type: Line Area OHLC

Advanced Charts

Opinion

Micro cap biotech trading well below cash value: Stockhouse Ticker Trax

World class potential in developing new pharmaceutical products

Danny Deadlock   December 2, 2011
0 stars

Rare earth junior could have another good year ... or two

Plus being close to throwing in the towel on this tiny biotech play

Danny Deadlock   February 7, 2011
0 stars

Latest Bullboard Posts

  • press release

    2.5 stars

    Toronto, Ontario, JULY 25, 2014  Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the Corporation or Spectral) and Toray Industries,...

    2 stars


  • RE:RE:RE:RE:Mimetogen

    0 stars

    Restasis by Allergan dominates the dry eye disease (DED) market with yearly sales just shy of 1 billion.  Restasis is a whopping 15% of...

    2 stars


  • RE:RE:RE:Mimetogen

    3 stars

    thanks

    2 stars


  • RE:RE:Mimetogen

    0 stars

    I wouldn't think that the Valeant takeover of Bausch and Lomb effects anything.  Valeant acquired everything from B&L and so the...

    2 stars


  • RE:Mimetogen

    3 stars

    do you know how the bausch and lomb takeover effects the trial or is it business as usual with their trial. Can't find much on Valeant...

    2 stars